Xenetic Biosciences (NASDAQ:XBIO) Shares Down 1.2% – Here’s Why

Xenetic Biosciences, Inc. (NASDAQ:XBIO) dropped 1.2% during trading on Wednesday . The company traded as low as $2.31 and last traded at $2.42. Approximately 64,947 shares were traded during trading, an increase of 22% from the average daily volume of 53,173 shares. The stock had previously closed at $2.45.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Xenetic Biosciences in a report on Wednesday, October 8th. One analyst has rated the stock with a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, Xenetic Biosciences has an average rating of “Reduce”.

Xenetic Biosciences Stock Performance

The stock has a fifty day moving average of $3.53 and a 200 day moving average of $3.32. The company has a market capitalization of $5.54 million, a PE ratio of -1.18 and a beta of 2.40.

Xenetic Biosciences (NASDAQ:XBIO) last announced its quarterly earnings data on Wednesday, November 12th. The company reported ($0.33) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.49) by $0.16. Xenetic Biosciences had a negative net margin of 110.42% and a negative return on equity of 64.66%. The business had revenue of $1.03 million during the quarter. As a group, equities analysts predict that Xenetic Biosciences, Inc. will post -1.01 EPS for the current year.

Institutional Trading of Xenetic Biosciences

An institutional investor recently raised its position in Xenetic Biosciences stock. Sachetta LLC raised its position in shares of Xenetic Biosciences, Inc. (NASDAQ:XBIO) by 43.1% during the second quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 15,259 shares of the company’s stock after acquiring an additional 4,593 shares during the period. Sachetta LLC owned approximately 0.99% of Xenetic Biosciences worth $60,000 as of its most recent filing with the Securities & Exchange Commission. 15.12% of the stock is owned by institutional investors.

Xenetic Biosciences Company Profile

Xenetic Biosciences, Inc is a biopharmaceutical company focused on progressing XCART, a personalized CAR T platform technology engineered to target patient-specific tumor neoantigens. The Company is initially advancing cell-based therapeutics targeting the unique B-cell receptor on the surface of an individual patient’s malignant tumor cells for the treatment of B-cell lymphomas.